Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etoricoxib Prescribing Patterns and Adverse Events of Interest During Etoricoxib Treatment in UK Primary Care; an Updated Analysis

Trial Profile

Etoricoxib Prescribing Patterns and Adverse Events of Interest During Etoricoxib Treatment in UK Primary Care; an Updated Analysis

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Etoricoxib (Primary)
  • Indications Acute pain; Ankylosing spondylitis; Gout; Musculoskeletal pain; Osteoarthritis; Postoperative pain; Rheumatic disorders; Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 02 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 31 Mar 2016 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov record.
    • 31 Mar 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top